[go: up one dir, main page]

WO2018039422A1 - Détection non effractive de l'œsophage de barrett - Google Patents

Détection non effractive de l'œsophage de barrett Download PDF

Info

Publication number
WO2018039422A1
WO2018039422A1 PCT/US2017/048357 US2017048357W WO2018039422A1 WO 2018039422 A1 WO2018039422 A1 WO 2018039422A1 US 2017048357 W US2017048357 W US 2017048357W WO 2018039422 A1 WO2018039422 A1 WO 2018039422A1
Authority
WO
WIPO (PCT)
Prior art keywords
biomarker
muc2
sample
esophagus
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/048357
Other languages
English (en)
Inventor
M. Jonathan Bern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018039422A1 publication Critical patent/WO2018039422A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • This present disclosure relates generally to detection of precancerous conditions, especially Barrett's esophagus.
  • Esophageal adenocarcinoma is a major cause of cancer death in the United States and throughout the world. In 2014, there were 15,450 deaths from EAC in the United States alone. More disturbing is the increasing incidence of EAC. Over the past 20 years there has been an exponential increase in new EAC cases. Unfortunately, most EAC cases are only detected at a late stage when the patient presents with symptoms. EAC diagnosed at this advanced stage carries a very poor prognosis.
  • EAC begins as a precancerous lesion termed Barrett's esophagus (BE).
  • BE represents a change from the normal squamous lining of the esophagus to a more acid resistant type of mucosa. This cellular transformation is called specialized intestinal metaplasia.
  • the specialized intestinal metaplasia of BE is characterized by the development of mucin producing goblet cells.
  • GCEVI goblet cell intestinal metaplasia
  • EMR endoscopic mucosal resection
  • EAC electrosplasia
  • AGA American Gastroenterological Association
  • an office based non-invasive screening test for detection of Barrett's esophagus BE.
  • over expression of specific molecular target molecules is used for the diagnosis of BE.
  • the molecular targets are detected by quantitative reverse transcriptase PCR (RT-qPCR).
  • RT-qPCR quantitative reverse transcriptase PCR
  • molecular targets are CDX2, MUC2, MUC5UA, BMP4, villin and combinations thereof.
  • a diagnostic test includes collection of esophageal brushings and testing for expression of one or more of MUC2 and CDX2, wherein expression of MUC2 and/or CDX2 in the esophagus is diagnostic for Barrett's esophagus. (BE). In certain embodiment testing for expression of BMP4 is added.
  • a method for diagnosis of BE including: a) obtaining a sample of esophageal cells from a subject; b) extracting nucleic acid from the sample; c) amplifying mRNA from the extracted nucleic acid using primers specific for expression from one or more of MUC2 and CDX2 genes; d) comparing an expression level of one or more MUC2 and CDX2 with expression levels of one or more housekeeping genes obtained from samples of cells from the subject to establish a gene expression level ratio for one or more of MUC2 and CDX2 in esophageal cells from the subject, e) determining that the ratio established in step d) is significantly different from expression of housekeeping gene(s) tested, and f) diagnosing said subject as having Barrett's esophagus.
  • the expression of the genes is measured by a quantitative method selected from the group consisting of RT-qPCR, northern-blotting, microarray and SAGE.
  • collected esophageal cells are washed with a buffer such as phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the washed solution is assayed for MUC2 by enzyme linked immunosorbent assay (ELISA).
  • ELISA enzyme linked immunosorbent assay
  • aliquots of collected cells are assayed for MUC2 and/or CDX2 by immunoassay.
  • testing for expression of BMP4 is added.
  • a method of diagnosing BE inducing the steps of: (a) determining an expression profile of a predetermined set of mRNAs in an esophageal sample from a patient by an RNA reverse transcription reaction using mRNA-specific primers, and (b) comparing the expression profile of the predetermined set to a reference expression profile, wherein the comparison of the expression profile of the predetermined set with the reference set allows for diagnosis of Barrett's esophagus, and wherein the predetermined set of mRNAs diagnostic for Barrett's esophagus comprises at least MUC2 and CDX2 mRNA.
  • a patient suspected of having or being at risk for BE is tested by collection of esophageal cells by a tethered device that is swallowed and then recovered per orum via the tether. Cells from a surface lining of the esophagus are isolated from the device and mRNA is extracted from the cells.
  • the device is a swallowed mesh sponge that is disposed in a gelatin capsule for swallowing and expands to fit against esophageal walls prior to being recovered.
  • Fig. 1 shows results of RT-qPCR detection of TFF3 in the 15 patients detailed in Fig. 4.
  • Fig. 2 shows results of RT-qPCR detection of MUC2 in the 15 patients detailed in Fig. 4.
  • FIG. 3 shows results of RT-qPCR detection of MUC5AC in the 15 patients detailed in Fig. 4.
  • Fig. 4 shows the biographical and medical histories of the 15 patients tested in Fig. 1 - Fig. 3.
  • Fig. 5 graphs the mean MUC2 ACt in the two groups of patients segregated by the diagnosis of Barrett's Esophagus on pathology.
  • Fig. 6 graphs the mean CDX2 ACt in two groups of patients segregated by the diagnosis of Barrett's Esophagus on pathology.
  • Fig. 7 depicts a ROC curve of the sensitivity and specificity of use of MUC2 expression as a marker in the accurate diagnosis of Barrett's esophagus as confirmed by pathology.
  • Fig. 8 depicts a ROC curve of the sensitivity and specificity of use of CDX2 expression as a marker in the accurate diagnosis of Barrett's esophagus as confirmed by pathology.
  • Fig. 9A shows the RT-qPCR results for detection of MUC2 by brushings obtained from 17 patients with histologically confirmed BE compared to brushings from 23 patients with normal squamous epithelium.
  • Fig. 9B shows the Delta delta Ct for MUC2 expression in BE brushings compared to normal squamous brushings.
  • Fig. 10A shows the RT-qPCR results for detection of CDX2 by brushings obtained from 17 patients with histologically confirmed BE compared to brushings from 23 patients with normal squamous epithelium.
  • Fig. 10B shows the Delta delta Ct for CDX2 expression in BE brushings compared to normal squamous brushings.
  • Fig. 11A shows the RT-qPCR results for detection of BMP4 by brushings obtained from 17 patients with histologically confirmed BE compared to brushings from 23 patients with normal squamous epithelium.
  • Fig. 1 IB shows the Delta delta Ct for BMP4 expression in BE brushings compared to normal squamous brushings.
  • an office based non-invasive screening test for detection of Barrett's esophagus BE.
  • over expression of specific molecular target molecules is used for the diagnosis of BE.
  • the molecular targets are detected by quantitative reverse transcriptase PCR (RT-qPCR).
  • RT-qPCR quantitative reverse transcriptase PCR
  • molecular targets are CDX2, MUC2, BMP4, villin and combinations thereof.
  • ⁇ - delta delta cycle threshold or also referred to as Normalized Cycles to Threshold
  • the phrase "at least one of when combined with a list of items, means a single item from the list or any combination of items in the list.
  • the phrase "at least one of A, B and C,” means “at least one from the group A, B, C, or any combination of A, B and C.”
  • the phrase requires one or more, and not necessarily not all, of the listed items.
  • BE represents a metaplastic change of the normal squamous esophagus, it results in several alterations in the cytopathology and molecular pathology of involved tissues. These include overproduction of two mucin species, mucin subtype 2 (MUC2) and mucin subtype 5AC (MUC5AC) and a marker for tissue metaplastic transformation, trefoil factor 3 (TFF3).
  • MUC2 mucin subtype 2
  • MUC5AC mucin subtype 5AC
  • TNF3 trefoil factor 3
  • TFF3 a marker for detection of BE in samples obtained with an esophageal cell sampling technique (CYTO SPONGE®).
  • CYTO SPONGE® an esophageal cell sampling technique
  • the present inventors determined that TFF3 does not specifically identify BE but is rather greatly influenced by inflammation making detection of TTF3 nonspecific and inappropriate for BE screening.
  • the present inventors undertook to identify molecular markers for BE that were both specific for BE and sensitive enough to be detected in samples obtained non-invasively.
  • CDX2 is a homeobox gene that encodes for an intestine- specific transcription factor, expressed in the nuclei of intestinal epithelial cells.
  • the NCBI Reference sequence of Homo sapiens CDX2 mRNA is NM_001265. This target protein is noted throughout the intestine, from duodenum to rectum.
  • CDX-2 is a marker of epithelial intestinal differentiation it should not be present in esophageal or gastric mucosa under normal circumstances.
  • CDX-2 When CDX-2 is seen in the esophagus it represents differentiation to intestinal epithelial cells. CDX-2 expression has been suggested as a marker for Barrett's esophagus when goblet cells cannot clearly be identified on histologic specimens. See Shi XY, et al. CDX2 and Villin Are Useful Markers of Intestinal Metaplasia in the Diagnosis of Barrett Esophagus. Am J Clin Pathol. 129(4) (2008) 571-7; Behan M, et al. Immunohistochemistry for CDX2 expression in non-goblet-cell Barrett's oesophagus. Br J Biomed Sci. 71(2) (2014) 86-92. Shi, XY et. al.
  • CDX2 appears to be a potent marker for intestinalization of esophageal mucosa with and without goblet cells.
  • serial biopsies over several years have demonstrated loss of goblet cells but continued strong immunohistochemical staining for CDX2. This indicates continued intestinalization of the esophageal mucosa in the absence of goblet cells.
  • the present inventors believe that BE is still present in patients despite the loss of characteristic goblet cells and that these patients continue to be at risk for esophageal cancer.
  • BMP-4 belongs to the transforming growth factor ⁇ family (TGF- ⁇ ) and has multiple roles in cell proliferation, differentiation and cell migration.
  • Bone morphogenetic proteins (BMPs) consist of more than 20 family members each having their own BMP-receptor affinity and regulating ligands. BMPs bind to transmembrane serine-threonine kinase receptors type 1 and 2 and activation of this leads to phosphorylation of SMAD1, 5 and 8, which permits binding to SMAD4. This complex translocates to the nucleus and regulates gene transcription specific for the BMP pathway. In the past BMP's were primarily felt to function during embryogenesis, however recent studies have shown that BMP's are overexpressed in various malignancies and may play a major role in cancer development. BMP-4 has been shown to be significantly upregulated BE and EAC.
  • Mucin 2 is particularly prominent in the gut where it is secreted from goblet cells lining the lumen of the large intestine.
  • the NCBI mRNA Reference Sequence is M_002457.4.
  • MUC2 along with other mucin proteins, polymerizes to form a gel. This gel provides an insoluble mucous barrier that protects the intestinal epithelium.
  • MUC2 should not be present in the esophagus or stomach under normal circumstances. Studies have shown that MUC2 serves as a marker for GCIM and NGIM. See e.g. Chinyama CN, et al.
  • Villin is a tissue-specific actin-binding protein associated with the actin core bundle of the brush border. Villin is believed to function in bundling, nucleation, capping and severing of actin filaments. Villin proteins help to support the microfilaments of the microvilli on the brush border of the intestine. This is an intestine specific protein and should not be found in the esophagus or stomach under normal circumstances and therefore may serve as a marker for BE. Shi XY et.al. ⁇ supra) found that 100% of biopsy with proven GCIM had villin by immunohistochemical staining.
  • patients are tested at the time of routine EGD.
  • the test is applied to patients that fall in to high risk groups for BE even if they are not overtly symptomatic.
  • BE is usually discovered during endoscopic examinations of middle-aged and older adults with symptomatic gastroesophageal reflux disease (GERD).
  • GERD gastroesophageal reflux disease
  • the mean age at the time of diagnosis is 55 years, with the highest prevalence rates noted for white and Hispanic men. Men are much more likely to develop BE compared to women with an odds ratio of 2.6 to one.
  • Asians and African Americans have significantly lower BE rates.
  • long-segment BE is found in 3 to 5 percent of the patients, whereas 10 to 15 percent have short-segment BE.
  • Obesity is a risk factor for both GERD and BE.
  • a 2009 meta-analysis that included 11 observational studies demonstrated an increased risk of BE in patients with a body mass index (BMI) >30 kg/m 2 as compared with patients with a BMI ⁇ 30 kg/m 2 (OR 1.4).
  • BMI body mass index
  • Other studies have shown that central obesity is an even more robust predictor of BE.
  • Central obesity in these studies is defined as a high waist to hip ratio (>0.9 in males and >0.85 in females).
  • Subjects with BE were also significantly more likely to currently or previously smoke or had ever smoked cigarettes compared to the general population (OR 1.67). Increasing pack-years of smoking correlates with increased the risk for BE.
  • the test is applied as a routine non-invasive office based test for a patient subset considered to be of increased risk for BE.
  • the patient subset is adult male patients over the age of 18 with intermittent or chronic GERD symptoms.
  • the patient subset includes individuals with known BE or previously treated BE that is being seen for surveillance endoscopy.
  • the biomarker testing is conducted on asymptomatic patients in the highest risk population.
  • testing is performed in middle aged (50 years and older) white or Hispanic men with central obesity having occasional or no GERD symptoms. This targeted approach is directed to capture the bulk of the at-risk population for EAC.
  • EGD with biopsy would be the next step. If high grade dysplastic (HGD) BE or early EAC were identified, EMR and RFA could be performed with a high chance for cure. If BE with low grade dysplasia (LGD) were identified, RFA alone could be performed with a high chance of cure. If non-dysplastic BE was identified, surveillance EGD could be performed looking for development of dysplasia or EAC and treatment. All patients with BE should be treated with a proton pump inhibitor to reduce the risk of malignant progression. See Singh, S., Garg, S.K., et. al.
  • Cells are sampled by a method that collects esophageal cells by a minimally invasive scraping or brushing procedure with a retrievable collection device that is swallowed.
  • the cells are collected with a cytological brush technique.
  • a tethered sponge disposed in a gelatin capsule is swallowed. When the capsule dissolves in the stomach and the sponge is released and withdrawn by the tether.
  • Esophageal brushings are tested by a method that measures the expression level of normal and marker genes in the esophagus by determining the amount of mRNA or of the cDNA corresponding to the genes.
  • the method is quantitative method.
  • Another method may utilize a predetermined cut off point separating a positive from negative result producing a qualitative result.
  • One such method for measuring relative amounts of mRNA expression is reverse transcription quantitative polymerase chain reaction (RT-PCR followed with qPCR).
  • RT-PCR initially generates a complementary DNA (cDNA template from the mRNA by reverse transcription.
  • the cDNA template is then used for qPCR where fluorescence of a probe changes as the DNA amplification progresses.
  • qPCR is able to quantitate the relative levels of mRNA species within the sample.
  • Another embodiment utilizes direct measurement of MUC2 and/or CDX2 protein levels by immunoassay on collected cells or from a supernatant solution of collected cells.
  • Levels of mRNA can also be quantitatively measured by other several methods including northern blotting which gives size and sequence information about the mRNA molecules including discrimination of alternately spliced transcripts.
  • Other methods known in the art include use of DNA microarrays and techniques such as Serial Analysis of Gene Expression (SAGE), which provides relative measures of different mRNAs.
  • SAGE Serial Analysis of Gene Expression
  • RT-qPCR was selected to evaluate relative expression of selected markers from cells obtained by esophageal brushing. Esophageal brushings are minimally invasive and represent little or no risk to the patient.
  • brushings are obtained from two locations for each patient: the suspected site of BE and normal squamous mucosa as an internal control.
  • two to four passes of the cytological brush are performed from each site and the brush is cut from the endoscopic appliance and placed in specimen containers.
  • the tissue and brush samples from each of the sites is placed RNA sample collection tubes such as for example RNAlater TissueProtect Tubes (Qiagen) in order to preserve the integrity of the RNA in the samples and then sent to the lab for immediate processing and storage at -20°C.
  • RNAlater TissueProtect Tubes Qiagen
  • a kit for use in identifying patients for whom further work-up is required to confirm BE or to establish a surveillance schedule.
  • the kit includes a swallowable tethered collection device in a sterile wrapper and an RNA sample collection tube including sample buffer wherein the tube includes a tag with identifies the patient and directs testing by Reverse Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR) for one or more of MUC2 and CDX2 together with testing of housekeeping gene expression.
  • RT-qPCR Reverse Transcriptase Quantitative Polymerase Chain Reaction
  • the kit is prepared for storage and transport to a testing facility that processed the sample in accordance with the directed testing.
  • RT-qPCR is sufficiently sensitive to detect and quantify very small amounts of target mRNA and therefore look for overproduction of specific proteins.
  • RT-qPCR uses gene amplification and therefore can detect very low mRNA levels.
  • RT-qPCR assays employ fluorescent reporter probes (i.e. TaqMan, Life Technologies) that can be designed for specific mRNA targets which results in minimal cross reactivity and high specificity.
  • the RT-qPCR assays employed have a 98% sensitivity over a 7-log concentration range with a gene amplification efficiency of over 98%.
  • Total RNA is isolated using standard protocols such as for example using the RNeasy mini kit with gDNA eliminator column (Qiagen Inc.). Total mRNA from each sample is converted to complementary DNA (cDNA) by available methods such as for example using the High Capacity RNA to cDNA kit (Life Technologies). Depending on the estimated numbers of calls collected, the cDNA may undergo preamplification such as for example using the TaqMan PreAmp Master Mix Kit (Invitrogen) prior to qPCR to amplify the cDNA targets equally without introducing bias while increasing the amount of total cDNA that may be required when assaying for multiple targets.
  • cDNA complementary DNA
  • the cDNA may undergo preamplification such as for example using the TaqMan PreAmp Master Mix Kit (Invitrogen) prior to qPCR to amplify the cDNA targets equally without introducing bias while increasing the amount of total cDNA that may be required when assaying for multiple targets.
  • MUC2, CDX2, BMP4 and villin mRNA expression levels are assessed using TaqMan Gene Expression Assay kits specific for these target proteins (Life Technologies).
  • Over expression of the target genes may be expressed in a number of ways including as an aggregate score of target gene expression over control gene expression or as over expression of an individual target gene. Target gene overexpression may also be expressed in absolute terms such as copies per microliter.
  • the RT-qPCR data is expressed in "Cycles to Threshold" (Ct). As understood by those of skill in the art, Ct is a relative value representing the cycle number at which the fluorescent signals of the amplified DNA reaches a determined threshold level that exceeds background.
  • Ct values are typically normalized against Ct amplification values for a constitutively expressed reference sequence such as a housekeeping gene.
  • differential expression is considered gene by gene and expressed as normalized Ct values (ACt) of biological replicates between groups of samples.
  • CT values are also referred to as AACt.
  • Ct levels are inversely proportional to the amount of target nucleic acid in the sample such that high ACt values represent low expression of a given gene while highly expressed genes have low ACt values. See e.g. Goni, R, et al. The qPCT Data Statistical Analysis. Integromics White Paper, September 2009, available on-line.
  • biopsies of suspected BE are obtained and sent for histologic evaluation by a gastrointestinal histopathologist. Such histology has historically served as the gold standard for the diagnosis of BE.
  • immunohistochemical stains are also examined for MUC2, CDX2, BMP -4 and villin. The RT- qPCR mRNA expression levels for the target proteins can be compared between suspected BE and normal squamous mucosa within each patient.
  • an office based screening test is provided to detect intestinalization of the esophagus, also known as intestinal metaplasia or Barrett's esophagus (BE).
  • the test will use a non-invasive cell sampling technique to obtain esophageal mucosal cells for analysis.
  • the cell sampling technique employs a course mesh collection device.
  • a suitable device is the CYTOSPONGE® (Medtronic GI Solutions), which is a single-use device used to collect cells from the lining of the esophagus. It consists of a small mesh sponge, about 30 mm in diameter, contained in a gelatin capsule and attached to a string.
  • the cell sampling device is placed in a buffer such as phosphate buffered saline (PBS) and agitated to free the cells from the sponge.
  • PBS phosphate buffered saline
  • the solution containing esophageal cells is centrifuged to form a cellular pellet.
  • the cellular pellet is placed in the RNA preservative.
  • the RNA preservative shall maintain the integrity of the RNA sample for at least 7 days at room temperature to allow transport and processing at a central laboratory facility.
  • Over expression of the target genes may be expressed as an aggregate score of target gene over expression or as over expression of an individual target gene.
  • a positive test is followed by EGD to confirm the diagnosis of BE and exclude dysplasia or EAC. If dysplastic BE or early EAC are identified, ablative techniques can be used to treat these conditions to prevent progression to invasive EAC.
  • the preferred ablative techniques are EMR and RFA although other techniques may be used depending on local expertise.
  • methods and kits that detect expression of one or more of MUC2, MU5AC, CDX2, BMP4 and villin, either directly or by detection of a corresponding mRNA and/or cDNA, including be including by quantitative reverse transcription polymerase chain reaction (RT-qPCR).
  • RT-qPCR quantitative reverse transcription polymerase chain reaction
  • an increase in expression of one of these proteins (or corresponding mRNA or DNA) is detected.
  • a decrease in expression of one of these proteins (or corresponding mRNA or DNA) is detected.
  • Detection of protein may be accomplished using numerous means including immunoassays such as enzyme linked immunosorbent assays (ELISA), using agglutination assays to measure protein content, radio-immunoassays, and using mass spectrometry to detect one or more characteristic fragment peaks of the proteins or by other methods.
  • immunoassays such as enzyme linked immunosorbent assays (ELISA), using agglutination assays to measure protein content, radio-immunoassays, and using mass spectrometry to detect one or more characteristic fragment peaks of the proteins or by other methods.
  • ELISA enzyme linked immunosorbent assays
  • mass spectrometry mass spectrometry to detect one or more characteristic fragment peaks of the proteins or by other methods.
  • the MUC2 and/or CDX2 concentration is determined by immunoassay of wash and/or carrier solutions.
  • aliquots of collected cells are tested for MUC2 and/or CDX2 and/or BMP4 expression by immunoa
  • the cell sampling device containing collected esophageal cells is placed in a buffer such as phosphate buffered saline (PBS) and agitated to free the cells from the sponge. At least a portion of the solution containing esophageal cells is used to assay for cellular expression of MUC2 and/or CDX2 by immunoassay, including by ELISA.
  • the cell sample is allowed to rest at room temperature or at 37° for a period of time such as for example approximately 10 minutes to approximately 30 minutes. The sample is centrifuged and an aliquot of the supernatant is removed for testing by immunoassay for MUC2 elaborated by the cells.
  • whole cells from the cell sample are assayed by immunoassay such as an ELISPOT assay using mesh filter plates in 96 well format and adapted to use on a vacuum manifold for washing.
  • the cell sample is centrifuged to collect a cell pellet.
  • the cells in the pellet are resuspended in a small volume and lysed such as by freeze thawing.
  • Cellular debris is removed such as by centrifugation and the cell lysate is testing by immunoassay for expressed levels of MUC2, CDX2 and BMP4.
  • target specific antibodies directed to the target protein are utilized.
  • binding detection may be obtained by enzyme or fluorescent labelled polyclonal detection antibodies.
  • Anti- human MUC2 antibodies may be obtained as murine monoclonals or rabbit polyconal antibodies from LSBio among others.
  • the methods and kits provide for non-invasive collection and may use a sponge, e.g., a capsule sponge, or other material that can be swallowable to collect cells along the esophagus by scraping or brushing.
  • a sponge e.g., a capsule sponge, or other material that can be swallowable to collect cells along the esophagus by scraping or brushing.
  • the exact nature of the sponge may vary, but in some instances, the sponge is cellulose based to permit digestion of the cellulose with an enzyme, e.g., a cellulase, and liberation of any cells within or on the sponge.
  • the cells can be lysed to release one or more of MUC2, MU5 AC, CDX-2, BMP -4 and villin proteins and any mRNA corresponding to the proteins.
  • Primers specific for one or more of MUC2, MU5AC, CDX2, BMP4 and villin are used to reverse transcribe the mRNA into a cDNA.
  • the cDNA levels are detected and used to determine if the subject is at risk for Barrett's Esophagus, has Barrett's Esophagus or has EAC .
  • the sponge can be coupled to a string or other device such that after the subj ect swallows the sponge, the sponge can be retrieved by pulling on the string.
  • Suitable primers and enzymes are commercially obtainable from Invitrogen to permit RT-qPCR of the mRNAs that encode one or more of MUC2, MU5AC, CDX2, BMP4 and villin.
  • the methods and kits may also be non-endoscopic.
  • the kit may be provided as an over the counter kit where the subject swallows the sponge to permit cell sampling of the esophagus.
  • the subject may then extract the sponge and place the sponge, e.g. after cutting of the string if desired, into a suitable buffer solution, e.g., phosphate buffered saline, or other solution to stabilize the cells or the mRNA species in the cells.
  • the sponge + buffer solution is shipped to a laboratory for analysis.
  • the solution may include cellulose or other enzymes if desired.
  • the solution may comprise detergents, salts, etc. to stabilize the cells or, if desired, lyse the cells.
  • the sponge can be shipped in dry ice or at a reduced temperature to reduce the likelihood of mRNA degradation.
  • Esophageal brushings were obtained at the time of EGD from 15 patients detailed in Fig. 4. Two female and 13 male patients were evaluated of which ten patients had a prior history of BE. Endoscopic diagnosis and biopsy evaluations showed either Short Segment BE (SSBE) or Long Segment BE (LS BE) in 13 patients while one received a normal endoscopic diagnosis. Three passes of the cytological brush were conducted and the brush cut from the endoscopic appliance and placed in RNAlater TissueProtect Tubes (Qiagen) and then sent to the lab for immediate processing and storage at -20°C. Total RNA was isolated using the RNeasy mini kit with gDNA eliminator column (Qiagen Inc.).
  • Total mRNA from each sample was converted to cDNA using the High Capacity RNA to cDNA kit (Life Technologies).
  • the cDNA was preamplified using the TaqMan PreAmp Master Mix Kit (Invitrogen division of ThermoFisher) prior to qPCR in order to amplify the cDNA targets.
  • TTF3, MUC2, MU5AC, CDX2, BMP4 primers were used for amplification using TaqMan Gene Expression Assay kits (InVitrogen division of ThermoFisher, Cat. #4331182).
  • the selected targets and amplicons are set out in Table 1.
  • TTF3 expression is presented in Fig. 1
  • data on MUC2 expression is presented in Fig. 2
  • data on MUC5 AC is presented in Fig. 3.
  • meaningful data was obtain using RTqPCR to determine levels of marker expression in samples collected by a retrievable cytological collection device.
  • TFF3, MUC2, MUC5AC were determined to be selective for BE based on subsequent analysis.
  • MUC2 was shown to be a viable marker for a BE screening test. It is normally only seen in the colon and is produced by mucin producing goblet cells. This marker should not be seen in the stomach or esophagus but is found in these locations in BE. Our preliminary results show significant overexpression of MUC-2 in BE and this correlates with histology for BE. This was true for non-goblet intestinalization (NGIM) and goblet cell intestinalization (GCIM).
  • NGIM non-goblet intestinalization
  • GCIM goblet cell intestinalization
  • CDX2 is a marker of intestinalization.
  • Our lab and others have found strong immunohistochemical staining in NGIM, GCIM and esophageal adenocarcinoma (EAC). This marker should not be found in the stomach or esophagus under normal circumstances. This is currently used in most advanced clinical pathology labs to confirm intestinal origin for tumors. The pathology findings from our study has resulted in routine use of immunohistochemical staining for CDX2 in suspected BE cases at our institution.
  • BMP4 is seen in BE and EAC by immunohistochemical staining and may relate to the pathogenesis of EAC.
  • a positive result by RT-qPCR for any of CDX2, MUC2 and BMP4 in samples collected with a non-invasive retrievable cytological collection device will stage the patient for further evaluation.
  • the immunohistochemical findings are a bit less overt under the microscope but the RT-qPCR result may correlate better with BE by histology.
  • MUC5AC was chosen based on review of the literature at the time. However, MUC5AC is also seen in the cardia of the stomach making this nonspecific for BE when considered in isolation. On the other hand, our data does show that MUC5AC correlates with BE in our studies and tracks along with MUC2. While this marker may not be specific enough for a BE screening test if considered in isolation, it remains a viable candidate marker when used together with other markers.
  • EGD esophagogastroduodenoscopy
  • NBI narrow band imaging
  • All EGD exams were performed by an experienced attending gastroenterologist.
  • a specialty trained GI histopathologist interpreted all pathology specimens.
  • 17 patients (42.5) were confirmed to have Barrett' s esophagus by pathology including detection of the presence of goblet cells in the esophagus, while 23 patients were confirmed to not have Barrett' s.
  • EGD despite being invasive and expensive, has relatively poor predictive value for the diagnosis of BE based on endoscopy findings when compared to histopathology by an expert GI histopathologist including the findings of goblet cells (the gold standard).
  • the control represents RT-qPCR data from esophageal brushings taken from the distal esophagus of the patient that proved not to have BE by histology but looked like BE at the time of EGD.
  • Table 3 shows an analysis of the AACt data together with verified detection of Barrett's by pathology.
  • Fig. 5 graphs the mean MUC2 AACt in the two groups of patients segregated by the diagnosis of Barrett's Esophagus on pathology.
  • Fig. 6 graphs the mean CDX2 AACt in the two groups of patients segregated by the diagnosis of Barrett's Esophagus on pathology.
  • Statistical analysis of the data showed the correlation between increased MUC2 and/or CDX2 expression and Barrett's esophagus confirmed by pathology was highly significant with a P value of ⁇ 0.001 by Student's 2 tailed t-test.
  • the expression of BMP4 does not differ significantly between patients with and without confirmed Barrett's esophagus.
  • ROC curves serve to plot the true positive rate against the false positive rate for different possible cutpoints of a diagnostic test.
  • a ROC curve demonstrates the tradeoff between sensitivity and specificity (with increases in sensitivity typically accompanied by decreases in specificity). The closer the curve follows the left-hand border and then the top border of the ROC space, the more accurate the test. In contrast, the closer the curve comes to the 45-degree diagonal of the ROC space, the less accurate the test.
  • AUC area under the curve
  • test result variable(s) Smaller values of the test result variable(s) indicate stronger evidence for a positive actual state.
  • test result variable(s) Smaller values of the test result variable(s) indicate stronger evidence for a positive actual state.
  • the test result variable(s): CDX2 Delta CT has at least one tie between the positive actual state group and the negative actual state group. Statistics may be biased.
  • the analysis identified two very useful markers for Barrett's esophagus are MUC2 and CDX2. To highlight the remarkably positive results.
  • the two tests are 100% sensitive with a 65% specificity making these very useful as screening tests for Barrett's esophagus. More importantly there were a very small number of subjects to get such strong results.
  • the AACt is a value obtained for both the BE esophageal brushings and normal squamous epithelium by subtracting out the house keeping gene values.
  • the ACt may be otherwise termed the normalized delta Ct or alternatively as AACt.
  • the term "ACt cutpoint of 10 or less" is defined as that obtained when the BE esophageal brushing data is compared with the ACt of esophageal brushings of normal squamous epithelium.
  • Fig. 9A shows the RT-qPCR results for detection of MUC2 by brushings obtained from 17 patients with histologically confirmed BE compared to brushings from 23 patients with normal squamous epithelium.
  • Fig. 9B shows the ACt for MUC2 expression in BE brushings compared to normal squamous brushings.
  • Table 8 shows the data presented in Fig. 9 A and
  • Table 9 shows the data presented in Fig. 9 A and Fig. 9B for BE epithelium.
  • Fig. 10A shows the RT-qPCR results for detection of CDX2 by brushings obtained from 17 patients with histologically confirmed BE compared to brushings from 23 patients with normal squamous epithelium.
  • Fig. 10B shows the ACt for CDX2 expression in BE brushings compared to normal squamous brushings.
  • Table 10 shows the data presented in Fig. 10A and Fig. 10B for normal squamous epithelium.
  • Table 11 shows the data presented in Fig. 10A and Fig. 10B for BE epithelium.
  • the lesion target gene ⁇ change is -15.02 with the fold increase in expression of CDX2 in BE tissue (2 A - AACt) is 33266.4836.
  • the significance of the difference by students t-test is ⁇ 0.0001 (7.39 x 10 -15).
  • Fig. 11A shows the RT-qPCR results for detection of BMP4 by brushings obtained from 17 patients with histologically confirmed BE compared to brushings from 23 patients with normal squamous epithelium.
  • Fig. 11B shows the ACt for BMP4 expression in BE brushings compared to normal squamous brushings.
  • Table 12 shows the data presented in Fig. 11A and Fig. 11B for normal squamous epithelium.
  • Table 13 shows the data presented in Fig. 11A and Fig. 11B for BE epithelium.
  • the lesion target gene ⁇ chang with the fold increase in expression of BMP4 in BE tissue (2 A - AACt) is 111.143.
  • the significance of the difference by students t-test is ⁇ 0.0001 (5.33 x 10 "8 ).
  • Claim 1 A method for diagnosing Barrett's Esophagus (BE) comprising: testing a sample of cells from an esophagus of a patient suspected of having BE for expression of an intestinal marker in the esophagus; comparing a relative expression of the intestinal marker with that of a constitutively expressed marker; establishing a ratio of the relative expression; and diagnosing the patient as having as having BE if the ratio of relative expression shows a presence of intestinal metaplasia in the esophagus.
  • Claim 2 The method of claim 1, wherein the sample is collected by esophageal brushing.
  • Claim 3 The method of claim 1, wherein the sample is collected by retrieval of a tethered cell collection device that is first swallowed, allowed to expand and then retrieved.
  • Claim 4 The method of claim 3, wherein the tethered cell collection device is a sponge compacted into a gelatin capsule that dissolves after being swallowed.
  • Claim 5 The method of claim 1, wherein the intestinal marker is one or more of the group consisting of MUC2 and CDX2.
  • Claim 6 The method of claim 1, wherein the intestinal marker is two or more of the group consisting of MUC2, CDX2 and BMP4.
  • Claim 7 The method of any one of claims 1 - 6, wherein the testing for expression of an intestinal marker in the esophagus is conducted by quantitative reverse transcriptase PCR (RT-qPCR).
  • Claim 8 The method of claim 7, wherein the patient is diagnosed as having BE when the ratio of relative expression is at ACt cutpoint of less than 10.
  • Claim 9 The method in any one of claims 1 to 8, wherein the protein is MUC2.
  • Claim 10 The method in any one of claims 1 to 8, wherein the protein is CDX2.
  • Claim 11 A method for diagnosing the presence of Barrett's Esophagus (BE) in a subject at risk of having BE, the method comprising: a) contacting a sample derived from esophageal cells collected from the subject with at least one biomarker reagent, wherein the at least one biomarker reagent includes a reagent that specifically binds to a MUC2 biomarker in the sample; b) measuring the level of the MUC2 biomarker in the sample; and c) detecting that the level of the MUC2 biomarker is increased in the esophageal sample relative to a control sample, thereby detecting the presence of BE in the subject.
  • BE Barrett's Esophagus
  • Claim 12 The method of claim 11, wherein the sample is collected by esophageal brushing.
  • Claim 13 The method of claim 11, wherein the at least one biomarker reagent further includes a reagent that specifically binds to a CDX2 biomarker in the sample.
  • Claim 14 The method of claim 11, wherein the at least one biomarker reagent further includes a reagent that specifically binds to a BMP4 biomarker in the sample.
  • Claim 15 The method of any one of claims 11 - 14, wherein the biomarker level is measured by RT-qPCR.
  • Claim 16 The method of any one of claims 11 - 14, wherein the biomarker level is measured by immunoassay, including by ELISA.
  • Claim 17 The method of claim 11, wherein the sample derived from esophageal cells collected from the subject is contacted with at least two biomarker reagents, wherein the at least two biomarker reagents include reagents that specifically bind to a MUC2 biomarker and a CDX2 biomarker and the MUC2 and CDX2 biomarkers are measured by RT-qPCR.
  • Claim 18 The method of claim 11, wherein the sample derived from esophageal cells collected from the subject is contacted with at least one additional biomarker reagent, wherein the at least one additional biomarker reagent is selected from a CDX2 biomarker reagent and a BMP4 biomarker reagent.
  • Claim 19 A method for diagnosing the presence of Barrett's Esophagus (BE) in a subject at risk of having BE, the method comprising: a) contacting a sample derived from esophageal cells collected from the subject with at least one biomarker reagent, wherein the at least one biomarker reagent includes a reagent that specifically binds to a MUC2 biomarker in the sample; b) measuring the level of the MUC2 biomarker in the sample by RT-qPCR; and c) detecting that the level of the MUC2 biomarker is increased in the esophageal sample relative to a control sample, thereby detecting the presence of BE in the subject.
  • BE Barrett's Esophagus
  • Claim 20 A method for diagnosing the presence of Barrett's Esophagus (BE) in a subject at risk of having BE, the method comprising: a) contacting a sample derived from esophageal cells collected from the subject with at least one biomarker reagent, wherein the at least one biomarker reagent includes a reagent that specifically binds to a MUC2 biomarker in the sample; b) measuring the level of the MUC2 biomarker in the sample by immunoassay; and c) detecting that the level of the MUC2 biomarker is increased in the esophageal sample relative to a control sample, thereby detecting the presence of BE in the subject.
  • BE Barrett's Esophagus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un test de dépistage non effractif pour la détection de l'œsophage de Barrett (BE) en cabinet de consultation. La surexpression de cibles moléculaires spécifiques est utilisée pour le diagnostic du BE. Dans certains modes de réalisation, les cibles moléculaires sont détectées par PCR quantitative à transcriptase inverse (RT-qPCR) Dans certains modes de réalisation, l'invention concerne un test diagnostique qui comprend un prélèvement cellulaire par cytobrosse œsophagienne et l'analyse de l'expression de MUC2 ou CDX2, ou des deux, l'expression de MUC2 et/ou de CDX2 au niveau de l'œsophage étant un marqueur diagnostique de l'œsophage de Barrett. Dans certains modes de réalisation, le test diagnostique peut également utiliser un test immunologique pour déterminer les concentrations en protéine MUC2, afin d'établir le diagnostic d'œsophage de Barrett.
PCT/US2017/048357 2016-08-24 2017-08-24 Détection non effractive de l'œsophage de barrett Ceased WO2018039422A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662379048P 2016-08-24 2016-08-24
US62/379,048 2016-08-24
US201662430059P 2016-12-05 2016-12-05
US62/430,059 2016-12-05

Publications (1)

Publication Number Publication Date
WO2018039422A1 true WO2018039422A1 (fr) 2018-03-01

Family

ID=61245330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/048357 Ceased WO2018039422A1 (fr) 2016-08-24 2017-08-24 Détection non effractive de l'œsophage de barrett

Country Status (1)

Country Link
WO (1) WO2018039422A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058316A1 (fr) * 2009-11-13 2011-05-19 Medical Research Council Dispositif d'échantillonnage de cellules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058316A1 (fr) * 2009-11-13 2011-05-19 Medical Research Council Dispositif d'échantillonnage de cellules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASTILLO, DANIEL ET AL.: "Activation of the BMP4 pathway and early expression of CDX2 characterize non-specialized columnar metaplasia in a human model of Barrett's Esophagus", JOURNAO OF GASTROINTESTINAL SURGERY, vol. 16, no. 2, 11 November 2011 (2011-11-11), pages 227 - 237, XP035006431 *
HU , YINGCHUAN ET AL.: "Pathogenesis of Barrett Esophagus: Deoxycholic acid up- regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells", ARCH. SURG., vol. 142, no. 6, 30 June 2007 (2007-06-30), pages 540 - 545 *
MURAO, TAKAHISA ET AL.: "Usefulness of endoscopic brushing and magnified endoscopy with narrow band imaging (ME-NBI) to detect intestinal phenotype in columnar-lined esophagus", JOURNAL OF GASTROENTEROLOGY, vol. 47, no. 10, 11 May 2012 (2012-05-11), pages 1108 - 1114, XP035127524 *
STEININGER, HELMUTH ET AL.: "Expression of CDX2 and MUC2 in Barrett's mucosa", PATHOLOGY-RESEARCH AND PRACTICE, vol. 201, no. 8-9, 10 October 2005 (2005-10-10), pages 573 - 577, XP025338607 *

Similar Documents

Publication Publication Date Title
US8709736B2 (en) Biomarker for Barrett's Oesophagus
JP6138154B2 (ja) 乳癌の予測および診断のためのバイオマーカー
Miyake et al. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer
US20110059452A1 (en) Methods of screening for gastric cancer
KR102384848B1 (ko) 방광암용 바이오마커로서의 케라틴 17
US20130090258A1 (en) Method for detecting colorectal tumor
US20240053343A1 (en) Biomarkers signature(s) for the prevention and early detection of gastric cancer
US9090933B2 (en) Cancer screening by detection of ultrastructural and molecular markers
Dellon et al. A single biopsy is valid for genetic diagnosis of eosinophilic esophagitis regardless of tissue preservation or location in the esophagus
CN113981087A (zh) 一种用于辅助诊断胃癌的生物标志物及其应用
US20110027797A1 (en) Method for the Diagnosis of Higher- and Lower-Grade Astrocytoma Using Biomarkers and Diagnostic Kit Thereof
Hata et al. Simultaneous and sequential combination of genetic and epigenetic biomarkers for the presence of high-grade dysplasia in patients with pancreatic cyst: Discovery in cyst fluid and test in pancreatic juice
JP6192122B2 (ja) 結腸直腸癌診断および予測のためのバイオマーカー
Kao et al. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods
Fujiya et al. Different gastric mucosa and CagA status of patients in India and Japan infected with Helicobacter pylori
CN110295230A (zh) 分子标志物inhba和spp1及其应用
WO2018039422A1 (fr) Détection non effractive de l'œsophage de barrett
WO2017098915A1 (fr) Marqueur du cancer du pancréas et des tumeurs intracanalaires papillaires et mucineuses
Murao et al. Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk
Allameh et al. Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects
JP6099109B2 (ja) 新規肺癌マーカー（ｌｉｐｈ）
JP4207187B2 (ja) 膀胱癌に対する分子マーカーとしてのｈｕｒｐ遺伝子
Khalid Differentiating neoplastic from benign lesions of the pancreas: translational techniques
CN104011198A (zh) Acf检测方法
KWAŚNIEWSKA et al. PREVALENCE OF CHLAMYDIA TRACHOMATIS IN CERVICAL AND VULVAR CARCINOMA

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17844391

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17844391

Country of ref document: EP

Kind code of ref document: A1